{"id":"androgen-receptor-targeted-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Sexual dysfunction"},{"rate":null,"effect":"Gynecomastia"}]},"_chembl":{"chemblId":"CHEMBL575966","moleculeType":"Small molecule","molecularWeight":"361.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Androgen receptor targeted therapies work by blocking or modulating the androgen receptor, a nuclear hormone receptor that drives proliferation in androgen-dependent cancers. By inhibiting this pathway, the drug suppresses tumor growth in conditions where androgen signaling is a primary driver. This approach is commonly used in prostate cancer and other androgen-responsive malignancies.","oneSentence":"This therapy targets the androgen receptor to modulate hormone-dependent signaling pathways, typically used in hormone-sensitive cancers.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:01:37.421Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer (likely indication given AR targeting and phase 3 status)"}]},"trialDetails":[{"nctId":"NCT07426094","phase":"PHASE2, PHASE3","title":"PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer","status":"RECRUITING","sponsor":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","startDate":"2026-03-19","conditions":"Prostate Cancer, Brachytherapy, Stereotactic Body Radiation Therapy (SBRT)","enrollment":1600},{"nctId":"NCT04689828","phase":"PHASE3","title":"177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-15","conditions":"Prostatic Neoplasms","enrollment":469},{"nctId":"NCT05658003","phase":"PHASE2","title":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-05","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":63},{"nctId":"NCT05573126","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":"Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT07335796","phase":"PHASE2","title":"A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-01-09","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT05022849","phase":"PHASE1","title":"A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-28","conditions":"Prostatic Neoplasms","enrollment":15},{"nctId":"NCT04720157","phase":"PHASE3","title":"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-09","conditions":"Prostatic Neoplasms","enrollment":1145},{"nctId":"NCT06691984","phase":"PHASE3","title":"Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-12-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":675},{"nctId":"NCT05647564","phase":"NA","title":"PET/CT Characterization of Treatment Resistance","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-03-06","conditions":"Prostate Cancer","enrollment":25},{"nctId":"NCT05818683","phase":"PHASE1","title":"A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-26","conditions":"Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer","enrollment":277},{"nctId":"NCT06836726","phase":"PHASE2","title":"Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-05-27","conditions":"Castration Resistant Prostate Cancer","enrollment":35},{"nctId":"NCT07364071","phase":"PHASE2","title":"Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-04","conditions":"Prostate Adenocarcinoma","enrollment":150},{"nctId":"NCT05983198","phase":"PHASE1, PHASE2","title":"Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-07","conditions":"Prostate Cancer","enrollment":29},{"nctId":"NCT04335682","phase":"PHASE2","title":"Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2021-08-17","conditions":"Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer","enrollment":111},{"nctId":"NCT04631601","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"TERMINATED","sponsor":"Amgen","startDate":"2021-01-15","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":65},{"nctId":"NCT05107674","phase":"PHASE1","title":"A Study of NX-1607 in Adults With Advanced Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2021-09-29","conditions":"Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer","enrollment":345},{"nctId":"NCT06520345","phase":"PHASE3","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-07-26","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":430},{"nctId":"NCT05191680","phase":"PHASE2","title":"TherApeutics in Early ProState Cancer (TAPS02)","status":"RECRUITING","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2023-04-24","conditions":"Prostate Cancer","enrollment":90},{"nctId":"NCT00001521","phase":"PHASE3","title":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1995-06-08","conditions":"Congenital Adrenal Hyperplasia (CAH)","enrollment":66},{"nctId":"NCT05839119","phase":"PHASE1","title":"Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant","status":"RECRUITING","sponsor":"Brown University","startDate":"2023-10-02","conditions":"Urothelial Carcinoma Bladder, Androgen Receptor Positive","enrollment":32},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT04916613","phase":"PHASE3","title":"ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-04-19","conditions":"Prostate Cancer Metastatic","enrollment":300},{"nctId":"NCT05352178","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligorecurrent Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-04-20","conditions":"Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic","enrollment":873},{"nctId":"NCT06473259","phase":"","title":"Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients","status":"RECRUITING","sponsor":"Santa Chiara Hospital","startDate":"2016-12-16","conditions":"Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Tumor","enrollment":3000},{"nctId":"NCT03554317","phase":"PHASE2","title":"COMbination of Bipolar Androgen Therapy and Nivolumab","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-09-05","conditions":"Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer","enrollment":45},{"nctId":"NCT04844749","phase":"PHASE3","title":"Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent","status":"TERMINATED","sponsor":"Veru Inc.","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer","enrollment":105},{"nctId":"NCT04869943","phase":"PHASE3","title":"Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Veru Inc.","startDate":"2021-10-12","conditions":"Metastatic Breast Cancer","enrollment":52},{"nctId":"NCT03840200","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-06-12","conditions":"Breast Cancer, Prostate Cancer, Ovarian Cancer","enrollment":51},{"nctId":"NCT03501173","phase":"","title":"A Study of Participants With Advanced Prostate Cancer in Canada","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2018-04-12","conditions":"Prostatic Neoplasms","enrollment":374},{"nctId":"NCT03458221","phase":"PHASE2, PHASE3","title":"Signal TrAnsduction Pathway Activity Analysis in OVarian cancER","status":"RECRUITING","sponsor":"Gynaecologisch Oncologisch Centrum Zuid","startDate":"2023-01-31","conditions":"Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation, Therapy-Associated Cancer","enrollment":148},{"nctId":"NCT03150056","phase":"PHASE1","title":"Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-07-18","conditions":"Solid Tumours","enrollment":73},{"nctId":"NCT02485691","phase":"PHASE4","title":"Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-09","conditions":"Prostate Cancer Metastatic","enrollment":255},{"nctId":"NCT04743388","phase":"","title":"Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System","status":"UNKNOWN","sponsor":"National and Kapodistrian University of Athens","startDate":"2021-01-04","conditions":"COVID-19, Healthy Volunteers, Chronic Disease","enrollment":600},{"nctId":"NCT03800784","phase":"PHASE2, PHASE3","title":"Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-10-01","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT02489123","phase":"PHASE2","title":"Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"University of Washington","startDate":"2015-08-11","conditions":"Ann Arbor Stage I Mantle Cell Lymphoma, Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma","enrollment":8},{"nctId":"NCT02924766","phase":"PHASE1","title":"A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-10-03","conditions":"Prostatic Neoplasms","enrollment":34},{"nctId":"NCT01790126","phase":"PHASE2","title":"The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2013-03-04","conditions":"Prostate Cancer","enrollment":90},{"nctId":"NCT01516866","phase":"","title":"Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2011-11","conditions":"Prostate Cancer","enrollment":58},{"nctId":"NCT02500901","phase":"PHASE1","title":"Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)","status":"TERMINATED","sponsor":"Paul Mathew, MD","startDate":"2016-03","conditions":"Metastatic Prostate Cancer","enrollment":2},{"nctId":"NCT00972023","phase":"PHASE1","title":"DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2010-02","conditions":"Breast Cancer","enrollment":1},{"nctId":"NCT02379390","phase":"PHASE2","title":"Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide","status":"TERMINATED","sponsor":"Sanofi","startDate":"2015-06-17","conditions":"Prostate Cancer Metastatic","enrollment":8},{"nctId":"NCT00589472","phase":"PHASE2","title":"Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-11","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":19},{"nctId":"NCT00539305","phase":"PHASE3","title":"Hormone and Information Processing Study","status":"COMPLETED","sponsor":"University of Washington","startDate":"2009-07","conditions":"Mild Cognitive Impairment, Alzheimer's Disease","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":55,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Androgen receptor targeted therapy","genericName":"Androgen receptor targeted therapy","companyName":"Universitaire Ziekenhuizen KU Leuven","companyId":"universitaire-ziekenhuizen-ku-leuven","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This therapy targets the androgen receptor to modulate hormone-dependent signaling pathways, typically used in hormone-sensitive cancers. Used for Prostate cancer (likely indication given AR targeting and phase 3 status).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}